Promising outcomes for multi-kinase inhibitors demonstrating anti-RET activity in NSCLC have been shown in numerous clinical trials, such as Vandetanib, Cabozantinib and Lenvatinib. This evidence concerns the gene RET and non-small cell lung carcinoma.